Bioequivalence Studies Reporting Rule Will Boost Submissions By 10% – FDA
A proposed rule to require ANDA sponsors to submit all bioequivalence studies they complete would increase annual BE study reports by 10%, FDA estimates
You may also be interested in...
FDA proposes amending its ANDA in vivo bioequivalence regulations to require submission of data "from all BE studies the applicant conducts on a drug product formulation submitted for approval," instead of only those studies meeting the necessary BE criteria. The amended regs will require "all additional passing and nonpassing BE studies conducted" to be submitted "in either a complete or summary report," HHS' Unified Agenda for 2002 says. The advance notice of proposed rulemaking is due out in February. FDA is concerned that submissions often do not include failed BE studies (1"The Pink Sheet" Oct. 23, 2000, p. 25)...
SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011